3D Systems and Antleron Collaborating
3D Systems' MultiJet Printing and Figure 4 technologies combined with Antleron's bioengineering expertise to target bioprinting solutions with potential to improve personalized patient care.
October 24, 2019
3D Systems and Antleron, a developer of regenerative products and promoter of personalized patient care, are announcing a collaboration, intended to help advance and accelerate solutions in the biomedical industry. The companies will collaborate to support Antleron's development of bioprinting solutions using 3D Systems' printing technologies.
The 3D Systems/Antleron relationship addresses solutions for medical device applications, incorporating technologies such as 3D Systems’ ProJet MJP 2500 3D printer.
Antleron has created an R&D facility at its headquarters in Leuven, Belgium, a location known as an incubator for medical and life science innovation, including regenerative medicine, to support and validate customer projects in the field of 3D bioprinting. Antleron's “living therapy factory” merges cells, biomaterials, biologics, bioreactors and 3D Systems printers to accelerate the engineering of living therapies. Using quality-by-design and artificial intelligence the Antleron multidisciplinary specialists translate these core technologies into workflows that turn cells into therapies.
The 3D Systems/Antleron relationship addresses solutions for medical device and advanced therapy medicinal product (ATMP) applications, incorporating technologies that benefit the biomedical manufacturing process, beginning with 3D Systems' ProJet MJP 2500 and Figure 4 3D printers and portfolio of 21 biocompatible, USP Class VI materials; 3D Sprint and 3DXpert software, and post-processing equipment and processes.
The goal is to establish a flexible, scalable Digital Factory approach, built on modular, closed parametric processes that include digital monitoring and quality control for risk mitigation. An example is to advance the way cells and tissues are grown to enable the transition from a static 2D to bioreactor-based 3D cell culture. This can lead to new ways to manufacture functionalized medical implants, vaccines, cell therapies, and living tissues, the companies say.
“The vision of Antleron is to sustainably bring living therapies into the clinic. 3D printing is key to this endeavor, and we are eager to collaborate with 3D Systems and its experts,” says Antleron CEO, Jan Schrooten. “I look forward to the pioneering solutions we'll be able to achieve to elevate the efficacy of bioprinting and extend its biomedical application reach.”
“3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capability to develop end-to-end solutions utilizing the 3D Systems' state of the art printing platforms and materials,” says Chuck Hull, co-founder and chief technology officer, 3D Systems. “As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D printing, and we look forward to expanding the role 3D Systems will play in these exciting fields.”
At Formnext 2019 in Frankfurt, Germany, November 19-22, 3D Systems (booth D03, hall 12.1) and Antleron will exhibit what is in store for next-generation medical applications with the ProJet MJP 2500 printer and VisiJet materials.
Sources: Press materials received from the company and additional information gleaned from the company’s website.
More 3D Systems Coverage
About the Author
DE’s editors contribute news and new product announcements to Digital Engineering. Press releases can be sent to them via [email protected].Follow DE